1. Patients with a known allergy or hypersensitivity to avelumab, 5-azacytidine, or any of their components. Known severe hypersensitivity reactions to monoclonal antibodies (Grade >/= 3 NCI CTCAE v 4.03), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).